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Ceramide accumulation mediates inflammation, cell death and
infection susceptibility in cystic fibrosis
Abstract
Microbial lung infections are the major cause of morbidity and mortality in the hereditary metabolic
disorder cystic fibrosis, yet the molecular mechanisms leading from the mutation of cystic fibrosis
transmembrane conductance regulator (CFTR) to lung infection are still unclear. Here, we show that
ceramide age-dependently accumulates in the respiratory tract of uninfected Cftr-deficient mice owing
to an alkalinization of intracellular vesicles in Cftr-deficient cells. This change in pH results in an
imbalance between acid sphingomyelinase (Asm) cleavage of sphingomyelin to ceramide and acid
ceramidase consumption of ceramide, resulting in the higher levels of ceramide. The accumulation of
ceramide causes Cftr-deficient mice to suffer from constitutive age-dependent pulmonary inflammation,
death of respiratory epithelial cells, deposits of DNA in bronchi and high susceptibility to severe
Pseudomonas aeruginosa infections. Partial genetic deficiency of Asm in Cftr(-/-)Smpd1(+/-) mice or
pharmacological treatment of Cftr-deficient mice with the Asm blocker amitriptyline normalizes
pulmonary ceramide and prevents all pathological findings, including susceptibility to infection. These
data suggest inhibition of Asm as a new treatment strategy for cystic fibrosis.
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Abstract 
 
Microbial lung infections are the major cause of morbidity and mortality in the 
hereditary metabolic disorder cystic fibrosis (CF), yet the molecular mechanisms leading 
from mutated CF Transmembrane Conductance Regulator (CFTR) to lung infection are 
still unclear. Here, we show that ceramide age–dependently accumulates in the 
respiratory tract of uninfected CF–mice due to an alkalinization of intracellular vesicles 
in Cftr–deficient cells that results in an imbalance of the activities of acid 
sphingomyelinase (Asm) cleaving sphingomyelin to ceramide, and acid ceramidase 
consuming ceramide. Accumulation of ceramide causes CF–mice to suffer from 
constitutive age–dependant pulmonary inflammation, death of respiratory epithelial cells, 
deposits of DNA in bronchi and high susceptibility to develop severe Pseudomonas 
aeruginosa infections. Partial inhibition of Asm in Cftr–/–/Smpd1+/– mice or by 
pharmacological treatment of CF–mice with the Asm blocker amitriptyline normalizes 
pulmonary ceramide and prevents all pathological findings including susceptibility to 
infection. These data suggest inhibition of Asm as a novel treatment strategy in CF.  
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Introduction 
 
The genetic disorder cystic fibrosis (CF), which affects approximately 80,000 
individuals in Europe and North America, is caused by mutations in the CF 
Transmembrane Conductance Regulator (CFTR) gene1–3. Chronic microbial lung 
infections, most commonly caused by the opportunistic bacterial pathogen Pseudomonas 
aeruginosa, reduce the life expectancy of CF subjects due to excessive lung tissue 
remodelling and destruction4. How mutation or absence of CFTR, which is primarily 
expressed in ciliated and submucosal gland epithelial cells of the respiratory tract5,6, 
promotes pulmonary infections, is still incompletely understood. Several studies support 
the notion that CF cells and respiratory tissues exhibit a pro–inflammatory status, which 
may facilitate bacterial lung colonization and infection7–10. 
Here we investigated the role of sphingolipids in the pathogenesis of CF. CFTR 
belongs to the ATP binding cassette transporter family, which has been previously 
demonstrated to be involved in lipid transport11,12. Furthermore, studies indicate that 
defective CFTR leads to higher pH levels in intracellular organelles13,14, which might be 
important for the regulation of the cellular sphingolipid metabolism by enzymes with an 
activity peak at acidic pH values. Since sphingolipids are critically involved in the 
regulation of cell survival15,16, NFκB activation17 and expression of pro–inflammatory 
cytokines18, we hypothesized that an alteration of the sphingolipid metabolism may play 
an important role in the pathogenesis of CF lung disease.  
We demonstrate that deficiency of Cftr results in an accumulation of cellular 
ceramide in the respiratory tract of uninfected CF–mice. The accumulation was caused by 
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the alkalinization of Cftr–deficient vesicles in respiratory cells leading to an imbalance of 
the activities of the acid sphingomyelinase (Asm) and acid ceramidase. A similar 
accumulation of ceramide was detected in respiratory epithelial cells and airways of CF 
subjects. In CF–mice, the increased sphingolipid concentrations triggered chronic 
pulmonary inflammation, death of respiratory epithelial cells and deposition of DNA in 
bronchi, and resulted in high susceptibility to severe pulmonary P. aeruginosa infections. 
Normalization of pulmonary ceramide levels that was achieved by pharmacological and 
genetic blockade of Asm, prevented all pathological findings and, most importantly, 
protected CF–mice from severe pulmonary P. aeruginosa infections. 
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Results 
 
Cftr–deficiency and ceramide accumulation 
To test the hypothesis that deficiency of functional Cftr results in alterations of the 
sphingolipid metabolism in the respiratory tract, we determined the concentration of 
ceramide in the lung of two wild type mouse strains and in the mouse strains Cftrtm1Unc–
Tg(FABPCFTR) (abbreviated CftrKO) and B6.129P2(CF/3)–CftrTgH(neoim)Hgu (abbreviated 
CftrMHH, syngenic to C57BL/6). These mice lack functional Cftr in the respiratory tract 
(collectively named CF–mice). Our results demonstrated a significant increase of 
ceramide in lungs of Cftr-deficient mice compared to control animals (Fig. 1a). Notably, 
this increase was age–dependent, whereas ceramide levels did not differ with age in wild 
type mice.  
To identify cells accumulating ceramide in CftrKO and CftrMHH mice, we stained 
isolated bronchial epithelial cells with two different monoclonal antibodies to ceramide. 
Excessive ceramide accumulation was observed in ciliated respiratory cells of CF–mice, 
but not wild–type mice (Fig. 1b). To further locate ceramide over–expressing cells, we 
stained paraffin sections of lungs from wild–type, CftrKO and CftrMHH mice for ceramide. 
Ceramide accumulation was observed in the respiratory tract epithelium and the 
submucosa of CF–mice (Fig. 1c). Control stainings with irrelevant Cy3–coupled 
antibodies were negative (not shown). Alveolar epithelial cells that constitute the 
majority of cells in the lung, did not contain substantial amounts of ceramide, neither in 
wild–type nor in CftrKO and CftrMHH mice (Fig. 1c). Concurrent with the presence of Cftr 
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in macrophages14, we detected a 6–fold increase of ceramide in mouse lung macrophages 
obtained by pulmonary lavage  (data not shown). 
To address the topology of ceramide in respiratory epithelial cells, we performed 
confocal microscopy. These studies indicated a marked accumulation of ceramide–
containing vesicles in respiratory epithelial cells of Cftr–deficient mice, and also the 
accumulation of ceramide in other cell membranes (Fig. 1d). Fluorescence activated cell 
sorting (FACS) data confirmed the accumulation of ceramide–containing vesicles in lung 
extracts from Cftr–deficient mice (Fig. 1e) as indicated by the increased percentage of 
ceramide–positive vesicles. In addition, we detected an increase of the absolute ceramide 
amount in these vesicles as indicated by the increased Cy3–signal that measures binding 
of the Cy3–labelled antibodies to ceramide in the FACS studies. The FACS data 
demonstrated that the accumulation of ceramide–containing lysosomes already occured 
in young, 12 week old Cftr–deficient mice, but to a lower degree than in older mice. 
Analysis of samples from CftrKO revealed the same results.  
To further support the accumulation of ceramide in Cftr–deficient cells and to 
exactly localize ceramide, we performed immunogold electron microscopy on lung 
sections from wild–type and Cftr–deficient mice. Ceramide predominantly located to 
intracellular vesicles in Cftr–deficient respiratory epithelial cells versus normal control 
cells (Fig. 1f). The accumulation of ceramide was not restricted to cathepsin D positive 
lysosomes, but also observed in other vesicles.  
To test whether these findings in CF mouse strains are also relevant for CF subjects, 
we isolated nasal respiratory epithelial cells from adult CF subjects and healthy 
individuals and stained the cells for ceramide. Similarly, lung transplant material from 
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three CF subjects and lung material from three normal donors was stained. The results 
showed an accumulation of ceramide in the membrane of nasal epithelial cells (Fig. 1g), 
respiratory epithelial cells and submucosal glands (Fig. 1h) compared to the respective 
cells or tissues from healthy individuals. Quantification of the fluorescence in epithelial 
cells from 17 healthy and 18 CF individuals revealed a 4 ± 0.4–fold increase of the 
ceramide signal in cells from CF subjects (P < 0.01, t–test).  
 
Defective acidification and ceramide accumulation  
Recent studies showed that CFTR–deficiency in alveolar macrophages results in a 
lysosomal pH shift from pH 4.5 to at least pH 5.914. Other studies demonstrate that an 
increase of the pH to 5.9 reduces the Asm activity by only ~35%, while the activity of the 
acid ceramidase is reduced by more than 90% at this pH, in some respects mimicking 
Farber disease, which is caused by a deficiency of the acid ceramidase and results in an 
accumulation of ceramide19,20. Furthermore, at a pH of 5.9, the acid ceramidase exhibits a 
reverse activity producing ceramide, instead of consuming it19. The imbalance of the Asm 
and the Ac and the reverse activity of the acid ceramidase at a vesicular pH of 5.9 should 
result in a net accumulation of ceramide in an in vivo situation.  
To investigate this hypothesis, we determined the pH in cellular vesicles of 
respiratory epithelial cells from wild–type and 24–week old CF–mice. Measurements of 
the vesicular pH in Cftr–deficient respiratory epithelial cells employing lysosensor–green 
revealed an increase of the pH in these vesicles to a value of 5.9 (Fig. 2a). This increase 
was mimicked by adding the Cftr–inhibitor 172 to wild–type cells (Fig. 2a).  
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Next, we confirmed the pH dependency of Asm and acid ceramidase activity in 
mouse lung preparations (Fig. 2b) as well as the reverse activity of the acid ceramidase at 
ph 4.5, 5.0 and pH 5.9 (Fig. 2b). The data showed an almost complete inhibition of the 
Ac at pH 5.9. In fact, at this pH, the enzyme showed a reverse activity producing 
ceramide. In contrast, the activity of the Asm was reduced by only 35% at pH 5.9.  
To show that an inhibition of the acid ceramidase results in cellular ceramide 
accumulation, we inhibited the acid ceramidase in respiratory epithelial cells of wild type 
mice in vivo by inhalation of n–oleoylethanolamine. Alternatively, intracellular vesicles 
were alkalinized by inhalation of bafilomycin, nigericin, chloroquin or NH4Cl. The 
results confirmed that direct inhibition of the acid ceramidase or alkalinization of 
lysosomes increase concentrations of ceramide in wild–type respiratory cells (Fig. 2c). 
To directly demonstrate a critical role of the lysosomal pH for the accumulation of 
ceramide in Cftr–deficient cells, we acidified isolated vesicles from Cftr–deficient lung 
cells in vitro. In the FACS studies on isolated vesicles from Cftr–deficient lung cells that 
were either left at a pH of 5.9 or acidified to pH 4.5 (lower panels in Fig. 2d) the intensity 
of the Cy3–coupled antibodies to ceramide staining served to measure the amount of 
ceramide in a single vesicle. The data demonstrated that acidification of vesicles isolated 
from Cftr–deficient cells reduced the vesicular ceramide amount (Fig. 2d). Vice versa, 
alkalinisation of vesicles isolated from wild–type cells from pH 4.5 to pH 5.9 resulted in 
ceramide–accumulation.  
Previous studies demonstrated that Cftr also functions as a direct transmembrane 
transporter or regulator of the transmembrane transport of sphingosine–1–phosphate12. 
However, we did not detect a significant increase of sphingosine–1–phosphate levels in 
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CF–mice. Sphingosine was increased in lungs of CF–mice, but the total sphingosine 
amounts were 0.5 ‰ of those of ceramide suggesting that a defect in uptake of 
sphingosine–1–phosphate via Cftr might not be the major cause for ceramide 
accumulation in Cftr–deficient cells  (for further details see supplementary note 1 
online).  
 
Inhibition of the Asm normalizes ceramide  
Ceramide is generated in cellular membranes from sphingomyelin by the constitutive 
activity of Asm or by de–novo synthesis21–23. The data described above indicate that the 
accumulation of ceramide within the lung of Cftr–deficient mice is caused by an 
imbalance between Asm and acid ceramidase activities. Thus, the Asm might be a 
potential pharmacological target to manipulate the sphingolipid metabolism in CF–mice. 
We, therefore, tested whether inhibition of Asm normalizes the increased ceramide 
concentration in the respiratory tract of CftrKO and CftrMHH mice. Partial inhibition of 
Asm was achieved by intraperitoneal injection of amitriptyline (10 mg/kg twice daily for 
2.5 d), which induces a proteolytic degradation of Asm24 or by crossing CftrKO mice with 
Asm knock–out mice (Smpd1–/–) to obtain mice deficient for Cftr and heterozygous for 
Asm (CftrKO/Smpd1+/–) (Fig. 2e). Biochemical assays and immunofluorescence studies 
on respiratory epithelial cells from CftrKO, CftrMHH and CftrKO/Smpd1+/– mice revealed 
that amitriptyline–mediated degradation or heterozygosity of Asm almost normalized 
pulmonary ceramide levels in these mice (Fig. 2f,g). 
Amitriptyline has been recently shown to result in degradation of the acid ceramidase 
in addition to the Asm25. Our data indicated that amitriptyline in fact also reduced the 
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already very low acid ceramidase activity at pH 5.9, but also the ceramide–producing 
reverse activity of the acid ceramidase at this pH (Fig. 2e). Thus, inhibition of ceramide 
generation via Asm and acid ceramidase was the predominant effect of amitriptyline at 
pH 5.9 resulting in net–reduction of cellular ceramide. Since the specific activity of the 
Asm is approximately 40–fold higher than the reverse activity of the Ac and 250–fold 
higher than the ceramide–consuming activity of the Ac at a pH of 5.9, we assumed the 
Asm as the primary target of amitriptyline. This is also consistent with the observation 
that heterozygosity of the Asm, which does not affect acid ceramidase expression, also 
reduced ceramide levels in CF mouse lungs.  
 
Normal ceramide prevents P. aeruginosa infection  
To test the significance of these findings for bacterial lung infections in CF, we 
determined the susceptibility of wild–type, CftrKO and CftrMHH mice to develop 
pulmonary P. aeruginosa infections. Increased susceptibility of CF mice for P. 
aeruginosa lung infection has been reported previously26,27. While wild–type mouse 
lungs contained only ∼103 CFU of P. aeruginosa per 100 mg of homogenized lung tissue 
2 h after inoculation, CftrKO and CftrMHH mice were significantly more susceptible to 
infection, revealing ∼106 CFU of P. aeruginosa strain 762/100 mg lung tissue (Fig. 3a). 
Pharmacological or genetic inhibition of Asm protected CftrKO and CftrMHH mice from 
pulmonary P. aeruginosa infections. Amitriptyline–treated CftrKO or CftrMHH mice or 
CftrKO/Smpd1+/– mice, respectively, displayed substantially less P. aeruginosa CFU in the 
lung than the respective CF–mouse strains 2 h after intranasal inoculation with 108 CFU 
of P. aeruginosa 762 (Fig. 3a). Similar data were obtained after infection of CftrKO or 
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CftrMHH mice with P. aeruginosa strains 769 and ATCC 14115 (Fig. 3b). The 
susceptibility of CftrKO and CftrMHH mice to develop pulmonary P. aeruginosa infections 
increased with the age of the mice (Fig. 3a), corresponding to the age–dependent increase 
of pulmonary ceramide concentrations. A slightly increased susceptibility to bacterial 
infection was already detectable in CF animals at an age of 8 and 12 weeks (Fig. 3a) 
although the susceptibility of younger mice was much lower than in mice with 16 and 24 
weeks of age consistent with the lower accumulation of ceramide in young mice lungs.  
 Control experiments revealed that when mice were intranasally challenged with 
108 CFU of P. aeruginosa, almost all bacteria could be recovered from the noses of the 
mice 2 min after application, while the lungs were still free of pathogens (Fig. 3c). There 
was no difference in recovered CFUs between wild–type and CF–mice at this early time 
point. In the early phase, i.e. 15, 30 and 60 min after infection, P. aeruginosa migrated to 
the lower airways and bacterial numbers increased in the lungs of all mice to a similar 
degree (Fig. 3c). After approximately 60 min wild–type mice started to eliminate the 
bacteria, whereas in CF–mice bacteria started to grow exponentially. Infection of the 
mice with only 107 CFU resulted in approximately lower absolute numbers in the lung 2 
h after the infection, revealing again a marked difference in CFUs between wild–type and 
CF–mice as observed for the higher infections dose (Fig. 3c).  
We also challenged the lungs of Cftr–deficient and wild–type mice with 
Streptococcus pneumoniae, a pathogen, which rarely infects CF subjects. The data 
revealed no difference between the pulmonary infection of wild–type and CF–mice with 
S. pneumoniae (not shown). 
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Next, we explored the relation of P. aeruginosa lung colonization rates to mouse 
mortality. The analysis of the 7 d survival rates demonstrated that initially high P. 
aeruginosa CFU correlated with mortality, which was significantly reduced (P < 0.05) by 
pharmacological or genetic heterozygosity of Asm (Fig. 3d). 
 
Accumulated ceramide causes inflammation 
Next, we aimed to identify mechanisms how accumulated ceramide mediates the 
hypersusceptibility of CF–mice to develop P. aeruginosa infections. To this end we 
tested typical immunological changes in the respiratory tract that are known to increase 
the susceptibility to P. aeruginosa and/or have been demonstrated to be altered in CF 
cells or lung tissues7–10. CftrKO or CftrMHH mice exhibited a constitutive increase of 
interleukin (IL)–1 and keratinocyte–derived chemokine (KC), the mouse homologue of 
human IL–8, in their lungs (Fig. 4a). Genetic or pharmacological inhibition of Asm 
normalized levels of pulmonary IL–1 and KC/IL–8 in CF mice (Fig. 4a), suggesting that 
cytokine up–regulation is linked to ceramide accumulation in CF–mice. Of note, the 
mice, held in a pathogen–free environment, were free of any infection as defined by 
repeated microbial cultures of lung homogenates and serological testing for multiple 
microbial species. 
In addition to the age–dependent increases in ceramide, IL–1 and IL–8 expression, 
lung tissues of CF–mice exhibited an age–dependent increase of macrophage and 
neutrophil cell numbers that was corrected by genetic or pharmacological inhibition of 
Asm (Fig. 4b,c). Compared to wild–type, amitriptyline-treated or CftrKO/Smpd1+/- mice, 
CftrKO and CftrMHH mice exhibited significantly increased macrophage (Fig. 4b) and 
  – 14 – 
neutrophil (Fig. 4c) cell counts in the lung at an age of 30 and 52 weeks (*P < 0.05, ** P 
< 0.01). The high macrophage and neutrophil cell numbers were normalized in 
CftrKO/Smpd1+/– mice and upon treatment of CftrKO mice with amitriptyline (Fig. 4b,c). 
In CftrKO mice, macrophages clustered around mouse submucosal glands (Fig. 4d), the 
principal site of CFTR expression in humans6. Macrophages (Fig. 4e) and neutrophils 
(Fig. 4f) were also present in high numbers in the bronchial associated lymphatic tissue, 
while only marginal numbers of macrophages and neutrophils were present in the lungs 
of wild–type mice.  
 
Accumulated ceramide, cell death and deposition of DNA  
Besides its impact on cytokine expression and inflammatory cell recruitment, 
ceramide has previously been shown to be critically involved in the induction of cell 
death15,16. Therefore, we tested whether CF–mice display an increased death rate of 
respiratory epithelial cells and whether this contributes to the hypersusceptibility of CF–
mice to develop P. aeruginosa infections. 
Terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick–
end labeling (TUNEL) staining of lung sections of CftrKO or CftrMHH mice revealed a 
higher number of dead cells, dispersed in the respiratory mucosa of large and medium–
sized bronchi when compared to wild type mice, in which cell death was rarely observed 
(Fig. 5a,b). The rate of respiratory epithelial cell death was increased in CF–mice in an 
age–dependent manner starting with a few dead cells in the respiratory tract in 12 week 
old mice (Fig. 5b). The increased death rate of respiratory epithelial cells in CftrKO or 
CftrMHH mice was normalized by pharmacological or genetic inhibition of Asm (Fig. 
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5a,b) or application of the broad–spectrum caspase inhibitor benzyloxycarbonyl-valin-
alanin-aspartat-fluoromethylketon (zVAD) that has been previously shown to block 
apoptosis in vivo28 (Fig. 5a,b).  
Next, we investigated whether increased cell death, caused by the accumulation of 
ceramide in nasal and bronchial epithelial cells, resulted in DNA deposits on the 
respiratory epithelium. DNA deposits were detectable on the mucosal lung surface in 
12%–17% of bronchi in CftrKO and CftrMHH mice (Fig. 5c,d), compared to maximal 2% 
DNA deposits in wild type mice. Young, 12–week old mice displayed a small, but 
distinct increase of DNA deposits in bronchi (Fig. 5d). To test whether the increased cell 
death rate in CF–mice was linked to deposition of DNA in the airways of these mice, we 
treated CftrKO and CftrMHH mice with zVAD. ZVAD inhibited the formation of DNA 
deposits within airway mucus in CF–mice (Fig. 5c,d). Notably, pharmacological 
inhibition of Asm by amitriptyline, genetic heterozygosity of Smpd1 or inhalation of 
recombinant DNase also abrogated DNA deposition on the mucosal lung surface (Fig. 
5c,d). 
 
DNA deposits, P. aeruginosa adhesion and infection 
To investigate whether DNA deposits on the respiratory epithelium of CF–mice 
mediate adherence of P. aeruginosa, we distributed DNA on a respiratory cell line, which 
led to an increased adherence of P. aeruginosa along DNA fibers (Fig. 6a) indicating the 
importance of DNA for bacterial adhesion. Therefore, we treated both CftrKO and CftrMHH 
mice with either recombinant human DNase (rhDNase) or with zVAD prior to bacterial 
challenge. Both, rhDNase or zVAD treatment effectively reduced P. aeruginosa cell 
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numbers in lungs of CftrKO or CftrMHH mice (Fig. 6b), suggesting that DNA deposits 
derived from dead epithelial cells facilitate P. aeruginosa adhesion and infection. Neither 
rhDNase nor zVAD changed pulmonary ceramide levels (not shown).  
 
Accumulation of ceramide in CF–mice is reduced by a diet 
A recent study29 shows a decrease of ceramide in the lungs of Cftr knock out mice 
compared to their littermate controls, which seems to be inconsistent with our data. 
However, these studies employed mice that are completely deficient for Cftr. Mice 
completely lacking Cftr in the intestinum usually die after birth due to intestinal 
obstruction and therefore require a special liquid diet, for instance with PeptamenR 29. We 
demonstrate that this diet reduced ceramide levels and inhibited the Asm by a ~300% 
increase of cholesterol in the lungs of CF mice (Supplementary Fig. 1a-d online), 
effects that are consistent with the previously published interference of cholesterol with 
Asm-activity30 and were prevented by treatment with simvastatin31. 
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Discussion 
 
In the present study we demonstrate an age–dependent hypersusceptibility of CF–
mice to P. aeruginosa infection that is caused by increased cellular ceramide levels in the 
lungs of CF mice. Inhibition of Asm and/or acid ceramidase by treatment of CftrKO or 
CftrMHH mice with amitriptyline or by generation of CftrKO/Smpd1+/– mice normalized 
pulmonary ceramide levels, prevented pulmonary P. aeruginosa infections and increased 
survival of infected animals.   
According to current models, sphingomyelin is constitutively metabolized to 
ceramide by Asm and further degraded to sphingosine by acid ceramidase 32. This process 
is thought to be located predominantly in lysosomes but also in other membranes such as 
the plasma membrane. Our data indicate that acidification of intracellular vesicles 
mediated by Cftr presumably through the provision of counter ions to permit higher 
lumenal H+ concentrations14,33,34 is critical for the concerted regulation of ceramide by the 
activities of Asm and acid ceramidase. The alkalinization of Cftr–deficient vesicles in 
respiratory cells of CF mice to a pH of 5.9, results in an imbalance of the Asm and Ac 
activities with a reduced consumption of ceramide and, finally, a net accumulation of 
ceramide. Our FACS, confocal and electron microscopy studies indicate an increase in 
the number of ceramide–containing vesicles and increased ceramide concentrations 
within those vesicles and in the cell membranes of Cftr–deficient cells, predominantly in 
cells from older mice.  
Two previous reports support our notion of defective acidification as a result of 
diminished Cl– conductance in other CF cell types. These studies demonstrated defective 
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acidification in the Golgi/trans–Golgi network, prelysosomes and endosomes of CF–cell 
lines leading to abnormal glycosylation of membrane proteins13, and showed the same 
phenomenon in phagolysosomes of alveolar macrophages from Cftr–null mice leading to 
impaired bactericidal activity14. These results have been questioned.35,36 Methodological 
differences, particularly concerning the thiazolidinone CFTR inhibitor CFTRinh–172, 
which is very sensitive to storage in stock DMSO solutions at low temperature, may 
account for some of the discrepant results14,36. Independent of this controversy, it is 
difficult to compare data employing zymosan conjugates containing fluorescein and TMR 
in macrophages or cultured cells, 36 with our data employing lysosensor green on ex vivo 
epithelial cells.  
A decrease of ceramide levels rather than an accumulation of ceramide was observed 
by other investigators in CF–mice, fed with the liquid diet PeptamenR 29. Here we 
demonstrate that PeptamenR treatment results in a very high cellular concentration of 
cholesterol that in turn results in reduction of Asm activity and pulmonary ceramide 
concentrations. CF–mice might be in particular sensitive to changes in the cholesterol 
metabolism37, since cultured Cftr–deficient cells already display 1.5–fold higher 
cholesterol levels than normal cells. These levels are too low to alter the activity of the 
Asm as demonstrated in the present study, however when CF mice are fed the PeptamenR 
diet, cholesterol concentrations increase to such levels that Asm is severely affected. The 
increase in cholesterol concentrations is due to an impressive consumption of the diet by 
the mice (~75% of body weight in a 24–hour cycle) leading to liver steatosis38,39. It is 
obvious that such a consumption is hard to achieve in humans, with the result that 
cholesterol levels will not increase in humans and, hence, Asm levels will not be 
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changed. Further, any diet that requires a 300-400% increase of cellular cholesterol 
concentrations to be effective can not be used in humans due to the severe adverse effects 
of high cholesterol. 
According to our data, showing a marked shift in ceramide and cholesterol levels, 
PeptamenR may have also been responsible for the observed essential fatty acid 
imbalance in CF–mice40. This notion is supported by studies showing that rats, fed diets 
containing cholesterol, significantly increase the cellular level of arachidonic acid, and 
the high arachidonic acid levels in hypercholesterolemic subjects, revealing high cellular 
cholesterol relative to the protein content41,42.  
We identified two mutually non–exclusive pathways, which may facilitate 
bacterial lung infection in CF as a consequence of abnormal ceramide accumulation: (i) 
the increased release of dead cells into respiratory airways, resulting in the formation of 
DNA deposits, which may serve as bacterial adherence factors, and, (ii) an increased 
inflammatory response. The latter may negatively affect lung function, innate immune 
responses and change the airway architecture to allow enhanced bacterial adhesion, but 
also lung fibrosis.  
 While the link between ceramide and the induction of cell death has been 
extensively documented15,16,43, conflicting results with regard to the rate of apoptosis in 
Cftr–deficient cells and mice prior44 and after45 P. aeruginosa infection have been 
previously described. Here, we show that an increased rate of cell death occurs only in 
the lungs of aged CF–mice, which was never investigated before. Increase of cell death is 
most probably caused in cells lacking functional Cftr by accumulated ceramide, since 
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Asm inhibition by amitriptyline or Asm heterozygosity in uninfected CF–mice reduce 
cell death to rates observed in wild type mice.  
The increased rate of cell death causes DNA deposition on the airway epithelium 
of CF–mice. DNA/mucus deposits may facilitate adhesion of P. aeruginosa to abiotic 
surfaces46, an event critical for the high susceptibility of CF–mice to develop P. 
aeruginosa infections. Accumulated ceramide per se does not seem to promote adhesion, 
since our experiments demonstrate that the adhesion of P. aeruginosa strains to washed 
nasal epithelial cells cultures from CF subjects and control individuals do not differ 
(unpublished data). 
Furthermore, it is conceivable that the accumulation of ceramide might severely 
impact the function of membrane rafts that were shown to be required for cell activation 
upon P. aeruginosa lung infections47. Curiously, feeding CF–mice with PeptamenR may 
also induce hypersusceptibility to infection. While ceramide selectively displaces 
cholesterol from ordered lipid rafts,48 high cholesterol levels may turn this reaction in the 
other direction, resulting in ceramide–poor cholesterol–rich rafts. Indeed, a significant 
improvement of Cftr–deficient mice to combat P. aeruginosa infection was reported 
when ceramide levels were normalized by treatment with Fenretinide29.  
Besides cell death, ceramide is also critically involved in the regulation of 
transcription factors17, which could subsequently lead to the release of cytokines and 
induce inflammation with age–dependent recruitment of effector cells in uninfected CF–
mice. How the accumulation of macrophages and neutrophils around submucosal glands 
contributes to the hypersusceptibility of CF–mice to P. aeruginosa lung infection remains 
to be defined. Both cell types have been implied in tissue remodeling mediated by the 
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production of reactive oxygen species, serine and metallo–proteases49, and their 
continuous exposure may affect submucosal gland structure and antimicrobial, anti–
inflammatory and anti–oxidant gland function and finally provoke fibrosis and 
emphysema49. 
As direct or indirect consequences of the increased ceramide concentrations in cells 
of the respiratory tract, our results unify several previously published observations in CF 
mouse strains with regard to inflammation9, apoptosis44,45 and hypersusceptibility to P. 
aeruginosa infection26,27. Furthermore, our findings emphasize that older animals are 
hypersusceptible to severe pulmonary disease, an observation in accordance with 
previous studies26.  
Our results strongly suggest that increased ceramide concentrations are 
deleterious for CF subjects and that reduction of such levels by amitriptyline might be 
beneficial. However, it is important to note that ceramide concentrations should not be 
reduced under a critical cellular level by a future drug to treat CF, which would impair 
the biological functions of ceramide. For example, we have previously shown that mice 
completely lacking Asm (Smpd1–/–) fail to adequately respond to acute infection with P. 
aeruginosa18. These mice are unable to clear bacteria from airways by epithelial cell 
internalization via ceramide–dependent rafts and subsequent degradation and also fail to 
control the infection18. Previous studies demonstrated that 5–15% residual activity of the 
Asm are sufficient to permit a normal response of epithelial cells to P. aeruginosa 
infection. Therefore, we employed in the present study mice heterozygous for the Asm. 
Thus, Asm–heterozygosity and treatment with amitriptyline in doses used here do not 
affect the ability of epithelial cells to adequately react to acute P. aeruginosa infections, 
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but they are sufficient to normalize ceramide levels in CF–mice. Consequently, a future 
drug, targeting ceramide to treat CF, should be carefully titrated to normalize ceramide 
levels in CF–lungs. A complete suppression of ceramide would paralyse early defense 
mechanisms of the host. This situation is reminiscent for many highly effective drugs, for 
instance anti–coagulants: given at doses that moderately suppress coagulation, these 
drugs may prevent heart and brain infarcts, while doses that result in a stronger blockade 
of coagulation may result in life threatening bleeding. 
In CF subjects expressing normal levels of Asm, the described pathophysiological 
events may provoke a vicious cycle, since P. aeruginosa triggers Asm activation, and, 
hence, ceramide release leading to apoptosis18.  Thus, the accumulation of ceramide on 
the respiratory epithelium, caused by the basic defect in CF, may still increase after the 
onset of chronic P. aeruginosa infection. In such a scenario, the increasing deposition of 
DNA (as a consequence of increased apoptosis) would further facilitate bacterial 
adhesion, impair mucociliary clearance by increasing the viscoelasticity of the airway 
surface liquid, and augment tissue destruction and remodeling by increasing 
inflammation.  
In summary, our data identify ceramide as one of the key regulators of 
inflammation and subsequent infection in CF airways. Normalization of ceramide levels 
by amitriptyline represents a novel strategy to prevent bacterial infections in CF subjects.  
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Methods 
 
Human subjects. We isolated ciliated epithelial cells from 18 CF subjects and 17 healthy 
control individuals (mean age 27 ± 7.8 years and 33 ± 6.5, respectively), attending the 
Eberhard–Karls–Universität, Universitätsklinikum, Tübingen, Germany. The study was 
approved by the ethic committee of the University of Tübingen, Tübingen, Germany. We 
obtained samples of normal lungs from three succumbed donors (mean age 26 years) in 
which the contralateral lung was not utilized for transplantation, and samples from the 
explanted lungs from three CF subjects receiving a double lung transplant, from the 
Deptartment of Pathology, University of Southern California, Los Angeles, USA, in 
compliance with the University of Southern California Institutional Review Board, Los 
Angeles, USA. We fixed bronchial tissue blocks (~ 1 cm3) in 10% paraformaldehyde, and 
embedded them in paraffin.  
 
Mice and treatments. For various treatment regimens, infection protocols and lung 
tissue investigations, different Cftr mutant mouse strains and their respective littermates 
were used (detailed methods in supplementary note 2 online). Amitriptyline was 
dissolved in distilled H2O and injected i.p. into mice at a dose of 10 mg/kg twice daily for 
2.5 d. ZVAD was injected i.p. at a dose of 8 mg/kg twice daily for 2.5 d. We fed mice if 
indicated with PeptamenR ad libitum. A single mouse consumed approximately 17–20 ml 
of the liquid diet daily, which is in accordance with previous reports38. In other 
experiments, mice inhaled 1 ml of the drugs Bafilomycin (1 µM), Nigericin (2.5 µM), 
NH4Cl (25 mM), chloroquine (10 µM), n–oleoylethanolamine (100 µM) and DNase (2.5 
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µg/ml, 25 µg/ml, 100 µg/ml and 1 mg/ml). Drugs were dissolved in 0.9% NaCl and 
inhaled for approximately 20 min. Furthermore, mice were intranasally infected with 107 
or 108 CFU of P. aeruginosa strains 762, 769 and ATCC 14115 or S. pneumoniae strain 
R6, employing a plastic–covered 30–gauge needle, which was inserted 2 mm into the 
nose with very short and light ether anesthesia50. P. aeruginosa cell numbers were 
determined in mouse lungs 15, 30, 60 or 120 min after challenge. Additionally, the 
survival of infected mice was determined for seven days after challenge. To reduce the 
variation associated with in vivo infectious experiments, we employed a standardized 
protocol (supplementary note 2 online). All procedures performed on mice were 
approved by the Animal Care and Use Committee of the Bezirksregierung Duesseldorf, 
Duesseldorf, Germany. 
 
Measurements of enzymes, ceramide, cell death, neutrophils, macrophages and 
DNA. We measured enzyme activities of Asm, acid cermidase and concentrations of 
ceramide and cholesterol in homogenized lungs from different mouse strains. Mouse 
lungs were homogenized in PBS in a dounce homogenisator for 30 sec. Additionally, we 
stained human or mouse lung sections for cell death using TUNEL, for ceramide using 
indirect immunofluorescence and electron microscopy, for neutrophils and macrophages 
using indirect immunofluorescence and for DNA. Finally, we determined concentrations 
of the cytokines IL–1 and KC in aliquots of homogenized mouse lungs using commercial 
ELISA assays, following the instructions of the manufacturer (R&D) and determined the 
adhesions of P. aeruginosa to DNA (supplementary note 2 online).  
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Isolation of cellular vesicles. We mechanically homogenized mouse lung tissue and 
incubated it for 30 min at 4 oC in 0.3 M sucrose, 10 mM TES, pH 7.4, and 0.5 mM EGTA 
to swell the cells. We disintegrated cells by 40x Dounce–homogenization, pelleted nuclei 
and unbroken cells by centrifugation for 5 min at 600 x g and 4 oC, and permeabilized the 
vesicles by 5 min incubation with 0.05% Triton X–100. Then we washed and stained 
vesicles with antibodies to ceramide (1:100) for 45 min at 4 oC, followed by staining with 
Cy3–coupled anti–mouse IgM antibodies and analysis by FACS.  
To investigate the role of the pH for ceramide accumulation, we isolated vesicles as 
above and incubated intact vesicles in 50 mM PIPES–KOH, 40 mM KCl, 10 mM NaCl, 2 
mM MgCl2, 2 mM EGTA, 10 µg/ml each aprotinin and leupeptin, 2 mM ATP, 10 mM 
phosphocreatine, 5 mM succinate, 50 µg/ml creatine kinase and 1% fetal calf serum at a 
pH of 4.5 or 5.9. Then we incubated vesicles at 37 oC for 8 h, and analysed vesicles for 
ceramide by the DAG kinase assay (supplementary note 2 online). Alternatively, we 
fixed vesicles for 15 min with 2% paraformaldehyde, permeabilized them with 0.05% 
Triton X–100, stained them with Cy3–coupled antibodies to ceramide and analysed them 
by FACS. The intensity of the staining with Cy3–coupled ceramide-specific antibodies 
served to measure the amount of ceramide in a single vesicle. 
 
pH measurements. We incubated isolated respiratory epithelial cells from CF– and 
wild–type mice with 70 nM lysosensor–green D189 (Molecular Probes) for 15 min and 
immediately analyzed dye emission by fluorescence microscopy. To isolate intact 
epithelial cells, large bronchi and the trachea were removed, and cells were gently 
removed from the tissue surface. Typically, a total of 500 cells (100 epithelial cells from 
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five different mice) were analysed. To determine the pH, the fluorescence intensity in 
vesicles was determined by measuring the fluorescence intensity in areas of 1.5 x 1.5 
mm. Samples were located with minimum light exposure. Images were captured with 
excitation at 488 nm employing an argon laser and were recorded at 505 nm emission. 
The measured fluorescence intensity was compared with a standard curve. To obtain the 
standard curve, we permeabilized cells and resuspended them in H/S with a given pH of 
4.5, 4.7, 4.9, 5.1, 5.3, 5.5, 5.7, 5.9, 6.1, 6.3 and 6.5. We incubated cells for 15 min with 
70 nM lysosensor–green and determined the fluorescence intensity in an area of 1.5 x 1.5 
mm. The standard curve (random fluorescence units) then served to determine 
fluorescence intensity and, therefore, the vesicular pH in intact cells. If indicated, we 
incubated intact cells with 10 µM of the CFTR inhibitor CFTRinh–172 (Sigma) for 15 min 
prior to the addition of lysosensor–green. The inhibitor was present throughout the whole 
experiment. Since CFTRinh–172 is very sensitive to storage in stock dimethyl sulfoxid 
(DMSO) solutions at low temperature for prolonged periods of time, we used it 
immediately after solubilisation. 
 
Statistics. We expressed data as arithmetic means ± SD and performed statistical analysis 
as indicated. In the case that values were not normally distributed, exact Mann–Whitney 
tests were performed. For normal distributed values, one–way ANOVA was applied. 
Significances are indicated. Kaplan–Meyer curves were analyzed by the log rank test (P 
< 0.05). All data are obtained from independent measurements. 
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Legends 
 
Figure 1 Cftr–deficiency results in pulmonary ceramide accumulation. (a) Ceramide 
concentrations in homogenized lung tissues of CftrKO and CftrMHH mice of different ages. 
Wild type (wt) mice were either C3H (WT) or C57BL/6 mice (B6). Asterisks indicate 
significant differences compared to the respective wt mice (mean ± SD; *P < 0.05; ** P 
< 0.01; *** P < 0.001). (b–c) Accumulated ceramide, detected by fluorescence 
microscopy, in isolated epithelial cells (b) and epithelial cells and submucosa of lung 
tissues (c), from CftrKO and CftrMHH mice compared to WT and B6 mice. Alveolar 
epithelial cells do not show ceramide accumulation. Shown are representative results 
from 6 independent experiments. (L = lumen of the bronchus, E = epithelial cells, S = 
submucosa). (d–f) Accumulated ceramide in vesicles of Cftr–deficient epithelial cells 
versus wild type cells, detected by fluorescence confocal microscopy (d), FACS analysis 
(e) and immunogold electron microscopy (f). Confocal and FACS results represent 10, 
electron microscopy results three independent experiments. (g,h) Ceramide accumulation 
in nasal epithelial cells (g, stained with Cy3-coupled antibodies to ceramide) or in 
epithelial cells (h, upper panel) and submucosal glands (h, lower panel; arrow indicates 
submucosal glands, stained with Cy2-coupled antibodies to ceramide) of lung tissues 
from CF subjects versus healthy individuals. Shown are representative results from 18 CF 
and 17 healthy individuals (nasal respiratory cells) or three lung samples, respectively. 
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Figure 2 Influence of vesicular pH on ceramide levels. (a) Increased vesicular pH in 
Cftr–deficient mouse respiratory epithelial cells (~ pH 5.9), and in respective cells of WT 
mice treated with the CFTR–inhibitor CFTRInh–172 (CFTR-INH), detected by 
lysosensor–green staining. Shown are typical examples (upper panel) and the mean ± SD 
(lower left panel) of 5 independent experiments. Vesicular pH was calculated from a 
standard curve (lower right panel). (b) Influence of pH levels on activities of acid 
sphingomyelinase (Asm) and acid ceramidase (Ac). A pH shift from pH 4.5 to pH 6.0 
reduces Ac activity to cleave ceramide by ∼90%, while its activity to generate ceramide 
from sphingosine (reverse activity) increases and Asm activity is reduced by 35%, 
resulting in an Asm/Ac imbalance. (c) Ceramide accumulation in lung cells of wild type 
mice, treated with bafilomycin, nigericin, chloroquin or NH4Cl by inhalation. b and c 
show the mean ± SD of 5 independent experiments. (d) Acidification of vesicles from 
Cftr–deficient mice normalizes ceramide, whereas alkalinization of vesicles from wild 
type mice increases ceramide levels. Left panel: Data represent mean ± SD of 5 
independent studies with one mouse each. Right plots: Representative FACS plots from 3 
independent experiments display ceramide levels in untreated and acidified vesicles from 
16–week old CftrMHH mice. Three vesicle populations containing different ceramide 
levels are visible. Arrows indicate vesicles with high ceramide levels at pH 5.9, which are 
reduced by acidification to pH 4.5. (e-g) Treatment of Cftr–deficient mice with 
amitriptyline (Ami, indicated by +) or heterozygosity of Asm (Cftr–/–/Smpd1+/–) reduces 
Asm and acid ceramidase activities at pH 5.9 (e) and almost normalizes pulmonary 
ceramide levels in 24 week old mice (f,g). Ceramide levels were determined by DAG–
kinase assay (f) or fluorescence microscopy (g). Displayed are the mean ± SD or 
  – 36 – 
representative results of 6 independent experiments. Asterisks indicate significant 
differences compared to wt (a,e) or untreated mice (c,e) or as indicated (d,f) (ANOVA, 
*P < 0.05, ** P < 0.01, *** P < 0.001). 
 
Figure 3 Ceramide accumulation mediates hypersusceptibility of CF–mice to P. 
aeruginosa infection. (a, b) Cftr–deficient (CftrKO, CftrMHH) mouse lungs contain high 
colony forming units (CFU) of P. aeruginosa strain 762 (a), 769 or 14115 (b) 2 h after 
intranasal application, compared to wild–type mice (WT, B6), Cftr–deficient mice treated 
with amitriptyline (+), or Asm–heterozygous mice (Cftr–/–/Smpd1+/–). (c) Upper left 
panel: recovery of P. aeruginosa, strain 762, 2 min after intranasal application of 108 
CFU in different mouse strains. Lower panel: P. aeruginosa CFU in lungs of different 
mouse strains 15, 30, 60 and 120 min after challenge with 108 CFU of P. aeruginosa. 
Upper right panel: P. aeruginosa CFU in lungs of different mouse strains 120 min after 
challenge with 107 CFU of P. aeruginosa. (d) Increased mortality of Cftr–deficient mice, 
infected intranasally with 108 CFU of P. aeruginosa strain 762, compared to wild type 
mice, is prevented by pharmacological inhibition or heterozygosity of Asm. Data (a-c) 
represent means ± SD of 6 independent experiments (*P < 0.05, ** P < 0.01, *** P < 
0.002; exact Mann–Whitney test) and Kaplan–Meyer curves (d) (*P < 0.05; log–rank 
test). 
 
Figure 4 CF–mice suffer from constitutive pulmonary inflammation corrected by 
normalization of pulmonary ceramide levels. Amitriptyline-treatment (+) or Smpd1-
heterozygosity normalizes (a) cytokine levels (24 week old mice) and (b) macrophage 
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and (c) neutrophil cell numbers in lungs of aged CF–mice that are constitutively 
increased in uninfected aged CftrKO and CftrMHH mice versus wild type mice. Data 
represent means ± SD of six independent experiments (ANOVA, *P < 0.05, ** P < 0.01 
between age-matched wild–type, amitriptyline-treated CF–mice or CftrKO/Smpd1+/- and 
CftrKO or CftrMHH mice). Numbers of fluorescent cells were determined microscopically. 
(d) Fluorescent-labelled macrophages (light blue, left panel, arrow) accumulate around 
submucosal glands, stained with periodic acid Schiff reagent (red, right panel, arrow) (b = 
bronchus). (e) Fluorescent-labelled macrophages (green, upper left panel) accumulate in 
the submucosal lung tissue of uninfected CF–mice but not wild–type mice (lower left 
panel). Staining with 4,6–diamidino–2–phenylindole–dihydrochloride (DAPI) is shown 
for CF–mice in the upper right panel and for wild type mice in the lower right panel. (f) 
Fluorescent-labelled neutrophils (green, upper left panel) accumulate in the submucosal 
lung tissue of uninfected CF–mice but not wild–type mice (lower left panel). DAPI 
staining is shown for CF–mice in the upper right panel and for wild type mice in the 
lower right panel. 
 
Figure 5 Pulmonary ceramide accumulation results in constitutive increase of respiratory 
cell death and deposition of DNA on the respiratory epithelium. (a) Increased death of 
epithelial cells (red stained nuclei), dispersed in the mucosa of large and medium–sized 
bronchi in CftrKO and CftrMHH mice, stained by TUNEL. Amitriptyline-treatment, Smpd1-
heterozygosity or application of the caspase inhibitor zVAD normalizes the death rate. 
Representative stainings from 6 independent studies are shown. (b) Quantitative analysis 
of dead respiratory epithelial cells in different mouse strains. Data represent means ± SD, 
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counted in at least 10 bronchi/mouse of 6 mice per group. (c) CF–mice display increased 
DNA–deposits (arrows) on the mucosal surface of bronchi, which are prevented by 
pharmacological or genetic inhibition of the Asm, treatment with zVAD or inhalation of 
recombinant human DNase. DNA was stained in paraffin sections either by TUNEL 
(upper panel) or with ethidium bromide (lower panels) resulting in bright DNA staining. 
Arrows: DNA–deposits, E: epithelial cell layer; L: bronchial lumen. Representative 
stainings are shown of at least 10 bronchi/mouse from 6 mice/group. (d) Percentage of 
bronchi displaying one or more DNA–deposits (mean ± SD). (*P < 0.05, ** P < 0.01, 
*** P < 0.001; ANOVA). 
 
Figure 6 DNA deposits are critically involved in the high susceptibility of CF–mice to P. 
aeruginosa infection. (a) DNA distributed on A549 respiratory cells significantly 
increases adherence and growth of P. aeruginosa. Shown are representative photographs 
from 3 independent experiments. P. aeruginosa was stained by indirect 
immunofluorescence and A549 cells were counterstained with 4,6–diamidino–2–
phenylindole–dihydrochloride. (b) Treatment of CftrKO and CftrMHH mice with the 
caspase inhibitor zVAD or recombinant human DNase prior to bacterial challenge 
prevents pulmonary infection with P. aeruginosa. Data represent means ± SD from 6 
mice/group, studied in 6 independent experiments. Significant differences are indicated 
(*P < 0.05, ** P < 0.01, *** P < 0.001; ANOVA).  
 
